150 related articles for article (PubMed ID: 18057867)
1. Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
Park SJ; Choi IK; Seo HY; Sung HJ; Park KH; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Acta Haematol; 2007; 118(4):219-21. PubMed ID: 18057867
[No Abstract] [Full Text] [Related]
2. [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].
García-Valdés M; Miras López M; Garrido Corro B; De La Rubia Nieto A
Farm Hosp; 2012; 36(1):50-1. PubMed ID: 21514865
[No Abstract] [Full Text] [Related]
3. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Anzalone CL; Cohen PR; Kurzrock R; Cortes JE
Dermatol Online J; 2014 Jan; 20(1):21242. PubMed ID: 24456946
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
5. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
Parmar KK; King RS
Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
[No Abstract] [Full Text] [Related]
7. [Management of chronic myeloid leukemia].
Kubuki Y
Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
[No Abstract] [Full Text] [Related]
8. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
9. Skin and oral lesions associated to imatinib mesylate therapy.
Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
12. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia: where do we go now?
Cortés JE
Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
[No Abstract] [Full Text] [Related]
14. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
[No Abstract] [Full Text] [Related]
15. Therapeutic drug monitoring in CML patients on imatinib.
Blasdel C; Egorin MJ; Lagattuta TF; Druker BJ; Deininger MW
Blood; 2007 Sep; 110(5):1699-701; author reply 1701. PubMed ID: 17712052
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ; Talpaz M; Resta DJ; Peng B; Buchdunger E; Ford JM; Lydon NB; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers CL
N Engl J Med; 2001 Apr; 344(14):1031-7. PubMed ID: 11287972
[TBL] [Abstract][Full Text] [Related]
17. Leukemia. Q&A highlights.
Frame D; Sessions J; Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
[No Abstract] [Full Text] [Related]
18. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
19. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
Otrock ZK; Mahfouz RA; Fahed Z; Farhat FS; Ziade A; Nasr F; Kassem N; Abboud MR
Int J Hematol; 2012 Oct; 96(4):521-4. PubMed ID: 22961257
[No Abstract] [Full Text] [Related]
20. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
Ostro D; Lipton J
Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
